Influenza remains a leading cause of hospitalizations among older adults, whose immune systems weaken with age. The FLUNITY-HD study, a large pooled analysis, compared the effectiveness of high-dose influenza vaccines with standard-dose versions in adults aged 65 years and above.
Results showed that the high-dose vaccine significantly reduced flu-related hospitalizations, especially for complications such as pneumonia and heart failure. By containing four times more antigen, the high-dose formulation triggers a stronger immune response, helping older adults build better protection even when their immune systems respond less robustly.
The findings reinforce what clinicians have suspected: a one-size-fits-all vaccine doesn’t work for aging populations. As the burden of influenza grows with increasing life expectancy, high-dose vaccines could be a cost-effective strategy to reduce hospital stays and improve outcomes in this vulnerable group.
In essence, more antigen means more defense and fewer hospital beds filled during flu season. For older adults, choosing the high-dose flu shot might be a small decision with life-saving potential.
MBH/PS